13F Holdings
中文EN

BFNH BIOFORCE NANOSCIENCES HOLDINGS, INC.

Laboratory Analytical Instruments · OTC · SEC CIK 1310488 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY75.0%
TTM EPS YoY80.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-44.3%
ROA-28.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio7.23x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-17.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
SG&A expense$66,951$67,437$48,953$62,514$78,955
Pretax income-$489,951-$490,437———
Net income-$1.29M-$490,437-$471,953-$485,514-$501,955
EPS (basic)-0.04-0.02-0.02-0.02-0.02
EPS (diluted)-0.04-0.02-0.02-0.02-0.02
Weighted avg. shares (diluted)33.21M29.27M29.27M29.27M29.27M
Balance sheet
Cash & equivalents$786$862$638$734$11,105
Current assets$786$862$638$734$11,145
Total assets$786$862$638$734$11,145
Current liabilities$619,329$2.30M$1.82M$1.35M$873,008
Total liabilities$619,329$2.30M$1.82M$1.35M$873,008
Shareholders' equity-$618,543-$2.30M-$1.82M-$1.35M-$861,863
Shares outstanding33.52M29.27M29.27M29.27M29.27M
Cash flow statement
Operating cash flow-$65,150-$61,250-$46,702-$68,389-$77,772
Financing cash flow$65,074$61,474$46,606$58,018$49,012

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.